Tech Company Financing Transactions
Carver Biosciences Funding Round
On 9/15/2022, Carver Biosciences announced funding from Khosla Ventures and private investors.
Transaction Overview
Company Name
Announced On
9/15/2022
Transaction Type
Venture Equity
Amount
Unknown
Round
Undisclosed
Investors
Khosla Ventures (Lead Investor) (Alex Morgan)
Proceeds Purpose
Carver will use the seed funding to conduct initial proof of concept Cas13 experiments in cells and in models of disease at their laboratories in Boston and with CRO partners.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Boston, MA Undisclosed
USA
Boston, MA Undisclosed
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Carver is a Boston, MA-based gene therapy company developing CRISPR-based therapies for RNA viruses that infect humans. Carver's approach is a programmable, platform technology that could offer a generalizable solution for treating many viruses, as targeting is dictated by a guide RNA sequence.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Walter Strapps
Co-Founder
Cameron Myhrvold
Browse more venture capital transactions:
Prev: 9/15/2022: Valve venture capital transaction
Next: 9/15/2022: Transaera venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs